In order to deliver a personalised, responsive service and to improve the site, we remember and store information about how you use it. This is done using simple text files called cookies which sit on your computer. By continuing to use this site and access its features, you are consenting to our use of cookies. To find out more about the way drugeruptiondata.com uses cookies please read our 'Cookie Policy'.
Litt's app available free to subscribers - download for IOS and Android from the App Store or Google Play.
- TRADE NAME: Zynlonta (ADC Therapeutics)
- INDICATIONS: Treatment of relapsed or refractory large B-cell lymphoma.
- CLASS: Alkylating agent, Antibody-drug conjugate (ADC), Biologic, CD19-directed antibody-drug conjugate, Monoclonal antibody
- HALF-LIFE: 21 days
- FDA APPROVAL DATE: 04/23/2021
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
None known - PREGNANCY: Can cause fetal harm when administered to pregnant women. Pregnancy testing is recommended for females of reproductive potential prior to initiating treatment. Advise women of reproductive potential to use effective contraception during treatment and for 9 months after the last dose.
- See adverse reactions attributed to class:
Loncastuximab tesirine is approved under accelerated approval based on overall response rate. Continued approval may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
Loncastuximab tesirine is a CD19-directed antibody and alkylating agent conjugate consisting of a humanized IgG1 kappa monoclonal antibody conjugated to SG3199, a pyrrolobenzodiazepine dimer cytotoxic alkylating agent, through a protease-cleavable valine-alanine linker. Treatment-emergent adverse events considered likely to be related to the pyrrolobenzodiazepine moiety include pleural effusion, adverse skin reactions and elevated liver enzymes.
Loncastuximab tesirine-lpvl is biosimiar
Please login to view the rest of this drug profile.
Page last updated 06/12/2024
